EmsanaRx, the upstart pharmacy benefit manager (PBM) that says its priority is public health, announced yesterday that it is changing its name to AffirmedRx.
EmsanaRx was launched in late 2021 as project of Emsana Health, an independent company established by The Purchaser Business Group on Health, a coalition of large employers. Emsana Health bills itself as an “innovation studio” for healthcare.
According to a press release Emsana Health sold its equity stake back EmsanaRx.
The press release says that AffirmedRx will continue EmsanaRx’s work “to create a completely unconflicted pharmacy benefit manager that all large self-funded employers can be proud to collaborate with.”
Greg Baker, CEO of EmsanaRx, is staying CEO of AffirmedRx, which has adopted “patients over profits” as it tagline. Like EmsanaRx, AffirmedRex is a public benefit corporation, a legal status that allows the company to prioritize public good and not just shareholders.
Baker says in the new name reflects “our commitment to forging new paths with members to deliver innovation and flexibility.”
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More